Riskpilot← Back to searchSign inGet full accessNYMØLLEVEJ ApS
APSActiveCVR 31155231Nymøllevej 6Construction of residential and non-residential buildings · NACE 4100Est. 2007— employees
Revenue 2025
DKK 58,9M
+3% vs 2024
EBITDA margin
100.0%
+3% vs 2024
Equity ratio
45.0%
Financial strength
Net profit 2025
DKK 32,3M
+6% vs 2024
| Revenue | DKK 58,9M | +3% |
| EBITDA | DKK 58,9M | +3% |
| Net profit | DKK 32,3M | +6% |
| Total assets | DKK 846,5M | +1% |
| Equity | DKK 380,9M | +1% |
| Employees | — | — |
Legal name
NYMØLLEVEJ ApS
CVR number
31155231
Legal form
Anpartsselskab
NACE code
4100 · Construction of residential and non-residential buildings
Founded
18. december 2007
Share capital
DKK 343.125.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør.
Company purpose
Selskabets formål er handel og investering.
Address
Nymøllevej 6
Phone
+4544355600
Email
nmv@widex.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.993 | 41.270 | 41.441 | 43.028 | 43.777 | 45.427 | 46.287 | 68.504 | 49.012 | 50.338 | 48.075 | 54.540 | 56.916 | 58.871 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 40.993 | 41.270 | 41.441 | 43.028 | 43.777 | 45.427 | 46.287 | 68.504 | 49.012 | 50.338 | 48.075 | 54.540 | 56.916 | 58.871 |
| Depreciation & amort. | -0 | -0 | -0 | -7.444 | -7.445 | -7.445 | -7.445 | -11.487 | -8.251 | -8.239 | -8.239 | -8.496 | -9.767 | -9.811 |
| EBIT | 40.993 | 41.270 | 41.441 | 35.585 | 36.332 | 37.982 | 38.842 | 57.017 | 40.762 | 42.099 | 39.836 | 46.044 | 47.150 | 49.060 |
| Net financials | -17.102 | -13.186 | -1.157 | -256 | 1.072 | 1.620 | -5.139 | -15.749 | 5.820 | 23.293 | -8.121 | -3.368 | -7.546 | -8.042 |
| Profit before tax | 23.891 | 28.084 | 40.284 | 35.329 | 37.404 | 39.602 | 33.703 | 41.268 | 46.582 | 65.392 | 31.715 | 42.676 | 39.603 | 41.018 |
| Tax | 5.973 | 7.021 | 4.611 | 7.978 | 8.229 | 8.712 | 7.415 | 9.079 | 9.272 | 15.362 | 6.977 | 9.389 | 9.025 | 8.711 |
| Net profit | 17.918 | 21.063 | 35.673 | 27.350 | 29.175 | 30.889 | 26.288 | 32.189 | 37.310 | 50.029 | 24.738 | 33.287 | 30.578 | 32.307 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 891.486 | 842.793 | 848.690 | 862.776 | 900.298 | 1.242.641 | 874.311 | 930.145 | 908.242 | 914.611 | 958.476 | 962.757 | 838.800 | 846.498 |
| Equity | 386.717 | 747.780 | 783.453 | 810.804 | 839.979 | 745.368 | 372.622 | 330.201 | 370.971 | 417.209 | 486.568 | 496.251 | 377.698 | 380.881 |
| Long-term debt | 0 | 0 | 0 | 3.227 | 3.885 | 439.342 | 439.565 | 463.635 | 436.206 | 400.563 | 385.691 | 368.080 | 377.317 | 376.946 |
| Short-term debt | 476.938 | 59.580 | 25.194 | 3.950 | 7.296 | 4.483 | 3.755 | 72.987 | 34.614 | 31.301 | 16.571 | 23.765 | 6.906 | 5.150 |
| Total debt | 476.938 | 59.580 | 25.194 | 7.177 | 11.181 | 443.825 | 443.320 | 536.622 | 470.820 | 431.864 | 402.262 | 391.846 | 384.223 | 382.096 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122025
Equity ratio
45.0%
This company
38.2%
Market median
+18% vs market
20122025
Return on equity
8.5%
This company
18.4%
Market median
-54% vs market
20122025
Net profit margin
54.9%
This company
8.1%
Market median
+578% vs market
20122025
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20122025
Debt / equity
1.22×
This company
0.62×
Market median
-97% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-05-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-05-01 – 2018-04-30
- Annual report 2017Filed via CVR / Virk · Period 2016-05-01 – 2017-04-30
- Annual report 2016Filed via CVR / Virk · Period 2015-05-01 – 2016-04-30
- Annual report 2015Filed via CVR / Virk · Period 2014-05-01 – 2015-04-30
- Annual report 2014Filed via CVR / Virk · Period 2013-05-01 – 2014-04-30
- Annual report 2013Filed via CVR / Virk · Period 2012-05-01 – 2013-04-30
- Annual report 2012Filed via CVR / Virk · Period 2011-05-01 – 2012-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JT Management | Management | 2008 | — | — |
SE Management | Management | 2008 | — | — |
LN Management | Management | 2015 | — | — |
AS Management | Management | 2007 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
T&W Medical A/S | Company | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
T&W Medical A/S
NYMØLLEVEJ ApS Board members of NYMØLLEVEJ ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Tøpholm | Management | 0 companies |
| Søren Erik Westermann | Management | 0 companies |
| Lars Nørgaard | Management | 0 companies |
| Anders Steen Westermann | Management | 0 companies |